DOI : 10.1055/s-00000059

Pneumologie

Issue S 01 · Volume 71 · March 2017 DOI: 10.1055/s-007-33496

Deutsche Gesellschaft für Pneumologie und Beatmungsmedizin e.V.
58. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e.V.
IC Stuttgart, 22.–25.03.2017

Kongresspräsidenten: Prof. Dr. med. Martin Hetzel, Stuttgart, Prof. Dr. med. Martin Kohlhäufl, Gerlingen; Kongresssekretär: Dr. med. Markus Zenner, Stuttgart
Abstracts (HTML) List of Authors
P30
Kreuter, M; Wacker, M; Hammerl, P; Wiederhold, C; Kabitz, HJ; Hagmeyer, L; Skowasch, D; Leidl, R; Hellmann, A; Pfeifer, M; Behr, J; Witt, S; Kauschka, D; Mall, M; Günther, A; Herth, FJF; Markart, P: Interims Analyse des EXCITING-ILD Registers (Registry for Exploring Clinical and Epidemiological Characteristics of Interstitial Lung Diseases)
P38
Kreuter, M; Bonella, F; Maher, TM; Costabel, U; Spagnolo, P; Weycker, D; Kirchgaessler, KU; Kolb, M: Impact of statins on lung function decline in idiopathic pulmonary fibrosis (IPF)
P51
Costabel, U; Nathan, SD; Lancaster, L; Albera, C; Glassberg, MK; Swigris, JJ; Gilberg, F; Kirchgaessler, KU; Petzinger, U; Noble, PW: Dose modifications and dose intensity during treatment with pirfenidone
P52
Costabel, U; Albera, C; Kirchgaessler, KU; Gilberg, F; Petzinger, U; Noble, PW: Analysis of patients with idiopathic pulmonary fibrosis (IPF) with percent predicted forced vital capacity (FVC) < 50% treated with pirfenidone in RECAP
P53
Costabel, U; Noble, PW; Albera, C; Kirchgaessler, KU; Gilberg, F; Petzinger, U: Benefit of treatment with pirfenidone (PFD) persists over time in patients with idiopathic pulmonary fibrosis (IPF) with limited lung function impairment
P54
Costabel, U; Swigris, JJ; Ley, B; Stauffer, J; Chou, W; Raimundo, K; Collard, H: Reduction in Non-Elective Respiratory-Related Hospitalizations in Patients Treated With Pirfenidone: Pooled Analyses from Three Phase 3 Trials of Pirfenidone in Idiopathic Pulmonary Fibrosis
P55
van Manen, M; Birring, SS; Vancheri, C; Wapenaar, M; Cottin, V; Wijsenbeek, MJG: Effect of Pirfenidone on cough in patients with Idiopathic Pulmonary Fibrosis
P170
Costabel, U; Flaherty, KR; Brown, KK; Stansen, W; Schlenker-Herceg, R; Raghu, G: Cumulative distribution of patients by change in FVC % predicted in the INPULSIS trials of nintedanib in patients with idiopathic pulmonary fibrosis
P173
Gläser, S; Maher, TM; Flaherty, KR; Azuma, A; Cottin, V; Stansen, W; Quaresma, M; Wells, A: Effect of nintedanib on decline in forced vital capacity (FVC) over time in the INPULSIS trials in patients with idiopathic pulmonary fibrosis (IPF)
P175
Behr, J; Raghu, G; Inoue, Y; Cottin, V; Stowasser, S; Stansen, W; Maher, TM: Effect of nintedanib on disease progression in the INPULSIS trials in patients with idiopathic pulmonary fibrosis (IPF)
P177
Kreuter, M; Crestani, B; Quaresma, M; Kaye, M; Stansen, W; Stowasser, S: Long-term treatment with nintedanib in patients with IPF: an update from INPULSIS-ON
P178
Neurohr, C; Richeldi, L; Azuma, A; Selman, M; Tang, W; Capapey, J; Stowasser, S; Cottin, V: Twenty-four week decline in forced vital capacity (FVC) predicts mortality at week 52 in the INPULSIS trials
P179
Pfeifer, M; Maher, TM; Flaherty, KR; Inoue, Y; Richeldi, L; Selman, M; Stansen, W; Stowasser, S; Wells, A: No effect of baseline diffusing capacity of lung for carbon monoxide on benefit of nintedanib
P185
Günther, JR; Neven, L; Schnabel, R; Schulte, PC: Case-Report: Gleichzeitige Diagnose einer Desquamativen interstitiellen Pneumonie und einer C-ANCA-positiven Vaskulitis mit Glomerulonephritis bei einem 46-jährigen Flugbegleiter
P202
Atug, E; Petermann, C; Schwarz, S; Wesseler, C; Gross-Fengels, W; Meierling, S; Wiest, GH: Erfolgreiche interventionelle Embolisation einer schweren pulmonalen Blutung bei Pulmonalarterienagenesie mit ausgeprägter Kollateralbildung